Sean Donahue
Concepts (542)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vision Screening | 37 | 2025 | 48 | 10.080 |
Why?
| | Oculomotor Muscles | 30 | 2026 | 86 | 9.660 |
Why?
| | Amblyopia | 42 | 2025 | 60 | 9.080 |
Why?
| | Ophthalmologic Surgical Procedures | 24 | 2026 | 90 | 7.200 |
Why?
| | Exotropia | 16 | 2026 | 25 | 6.050 |
Why?
| | Strabismus | 28 | 2026 | 71 | 5.890 |
Why?
| | Esotropia | 13 | 2023 | 30 | 4.410 |
Why?
| | Refractive Errors | 14 | 2022 | 36 | 3.210 |
Why?
| | Visual Acuity | 45 | 2026 | 490 | 3.160 |
Why?
| | Ophthalmology | 12 | 2026 | 120 | 3.000 |
Why?
| | Vision, Binocular | 18 | 2026 | 47 | 2.740 |
Why?
| | Posture | 6 | 2022 | 197 | 2.390 |
Why?
| | Head | 5 | 2022 | 123 | 2.390 |
Why?
| | Hyperopia | 12 | 2022 | 19 | 2.200 |
Why?
| | Anisometropia | 14 | 2022 | 18 | 2.030 |
Why?
| | Visual Field Tests | 13 | 2024 | 32 | 2.020 |
Why?
| | Retinopathy of Prematurity | 7 | 2023 | 181 | 1.990 |
Why?
| | Vision Disorders | 12 | 2019 | 179 | 1.970 |
Why?
| | Nystagmus, Pathologic | 3 | 2022 | 19 | 1.940 |
Why?
| | Child, Preschool | 76 | 2026 | 11868 | 1.830 |
Why?
| | Visual Fields | 17 | 2024 | 116 | 1.550 |
Why?
| | Infant | 56 | 2023 | 10090 | 1.520 |
Why?
| | Eye Abnormalities | 3 | 2019 | 17 | 1.520 |
Why?
| | Ocular Motility Disorders | 6 | 2022 | 42 | 1.420 |
Why?
| | Endophthalmitis | 12 | 2021 | 46 | 1.340 |
Why?
| | Child | 71 | 2026 | 22739 | 1.310 |
Why?
| | Eye Movements | 11 | 2021 | 94 | 1.310 |
Why?
| | Eyeglasses | 12 | 2014 | 24 | 1.290 |
Why?
| | Advisory Committees | 4 | 2018 | 229 | 1.270 |
Why?
| | Diplopia | 6 | 2024 | 28 | 1.250 |
Why?
| | Eye Infections, Fungal | 7 | 2021 | 19 | 1.230 |
Why?
| | Nystagmus, Congenital | 2 | 2020 | 4 | 1.230 |
Why?
| | Head Movements | 4 | 2020 | 37 | 1.220 |
Why?
| | Follow-Up Studies | 29 | 2026 | 5428 | 1.180 |
Why?
| | Humans | 182 | 2026 | 145763 | 1.180 |
Why?
| | Myopia | 5 | 2021 | 59 | 1.120 |
Why?
| | Astigmatism | 6 | 2021 | 17 | 1.040 |
Why?
| | Virtual Reality | 3 | 2024 | 82 | 0.990 |
Why?
| | Referral and Consultation | 10 | 2020 | 868 | 0.960 |
Why?
| | Predictive Value of Tests | 19 | 2022 | 2123 | 0.950 |
Why?
| | Tenotomy | 3 | 2019 | 22 | 0.940 |
Why?
| | Treatment Outcome | 34 | 2026 | 11793 | 0.900 |
Why?
| | Preventive Health Services | 3 | 2018 | 153 | 0.860 |
Why?
| | Photography | 6 | 2008 | 119 | 0.860 |
Why?
| | Retrospective Studies | 35 | 2024 | 17325 | 0.850 |
Why?
| | Trochlear Nerve Diseases | 2 | 2023 | 8 | 0.840 |
Why?
| | Papilledema | 3 | 2021 | 44 | 0.840 |
Why?
| | Pediatrics | 3 | 2026 | 1125 | 0.840 |
Why?
| | False Positive Reactions | 12 | 2021 | 123 | 0.830 |
Why?
| | Societies, Medical | 4 | 2026 | 900 | 0.820 |
Why?
| | Fungemia | 5 | 2011 | 10 | 0.810 |
Why?
| | Sensitivity and Specificity | 13 | 2023 | 2000 | 0.800 |
Why?
| | Tendons | 3 | 2014 | 132 | 0.790 |
Why?
| | Abnormalities, Multiple | 3 | 2016 | 199 | 0.790 |
Why?
| | Basal Cell Nevus Syndrome | 2 | 2014 | 7 | 0.760 |
Why?
| | Diagnostic Techniques, Ophthalmological | 4 | 2015 | 53 | 0.740 |
Why?
| | Male | 76 | 2026 | 73003 | 0.730 |
Why?
| | Optic Disk | 2 | 2021 | 53 | 0.710 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 115 | 0.700 |
Why?
| | Candidiasis | 5 | 2019 | 64 | 0.700 |
Why?
| | Atropine | 6 | 2011 | 37 | 0.670 |
Why?
| | Lens Implantation, Intraocular | 3 | 2008 | 80 | 0.660 |
Why?
| | Risk Factors | 20 | 2023 | 10917 | 0.650 |
Why?
| | Education, Medical, Graduate | 1 | 2026 | 562 | 0.650 |
Why?
| | Female | 67 | 2026 | 79035 | 0.630 |
Why?
| | Glaucoma Drainage Implants | 1 | 2020 | 46 | 0.610 |
Why?
| | Trabeculectomy | 1 | 2020 | 75 | 0.600 |
Why?
| | Eyelids | 1 | 2019 | 41 | 0.580 |
Why?
| | Eye Diseases | 2 | 2020 | 97 | 0.570 |
Why?
| | Remote Consultation | 1 | 2020 | 66 | 0.570 |
Why?
| | Adolescent | 29 | 2024 | 22573 | 0.560 |
Why?
| | Hemianopsia | 2 | 2008 | 11 | 0.550 |
Why?
| | Fixation, Ocular | 5 | 2020 | 28 | 0.550 |
Why?
| | Prevalence | 13 | 2025 | 2874 | 0.550 |
Why?
| | Duane Retraction Syndrome | 1 | 2017 | 1 | 0.540 |
Why?
| | Chorioretinitis | 4 | 2011 | 8 | 0.530 |
Why?
| | Bandages | 3 | 2016 | 41 | 0.530 |
Why?
| | Charities | 2 | 2008 | 12 | 0.520 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 209 | 0.510 |
Why?
| | Tonic Pupil | 1 | 2016 | 1 | 0.500 |
Why?
| | Glaucoma | 5 | 2021 | 251 | 0.500 |
Why?
| | Retina | 4 | 2016 | 329 | 0.500 |
Why?
| | Sleep Apnea, Central | 1 | 2016 | 13 | 0.500 |
Why?
| | Practice Guidelines as Topic | 6 | 2021 | 1582 | 0.490 |
Why?
| | Kidney Diseases, Cystic | 1 | 2016 | 24 | 0.490 |
Why?
| | Mydriatics | 6 | 2011 | 10 | 0.490 |
Why?
| | Hypoventilation | 1 | 2016 | 17 | 0.490 |
Why?
| | Ophthalmic Solutions | 3 | 2015 | 82 | 0.480 |
Why?
| | Technology Assessment, Biomedical | 2 | 2016 | 45 | 0.480 |
Why?
| | Retinal Neoplasms | 2 | 2013 | 42 | 0.470 |
Why?
| | Depth Perception | 4 | 2017 | 5 | 0.470 |
Why?
| | Retinoblastoma | 2 | 2013 | 47 | 0.470 |
Why?
| | Infant, Newborn | 13 | 2023 | 6464 | 0.460 |
Why?
| | Ophthalmoplegia | 4 | 2001 | 13 | 0.460 |
Why?
| | Refraction, Ocular | 3 | 2011 | 47 | 0.450 |
Why?
| | Prescriptions | 2 | 2007 | 74 | 0.450 |
Why?
| | Hirschsprung Disease | 1 | 2016 | 92 | 0.440 |
Why?
| | Eye Neoplasms | 1 | 2015 | 30 | 0.440 |
Why?
| | Sensory Deprivation | 7 | 2011 | 17 | 0.440 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 26 | 0.440 |
Why?
| | Lens, Crystalline | 2 | 2008 | 136 | 0.430 |
Why?
| | Uveitis, Anterior | 1 | 2015 | 27 | 0.430 |
Why?
| | Conjunctiva | 1 | 2015 | 52 | 0.430 |
Why?
| | Cerebellum | 1 | 2016 | 224 | 0.430 |
Why?
| | Optic Nerve Diseases | 5 | 2021 | 49 | 0.430 |
Why?
| | Mass Screening | 3 | 2020 | 1361 | 0.430 |
Why?
| | Pseudophakia | 1 | 2014 | 21 | 0.420 |
Why?
| | Tensile Strength | 1 | 2014 | 98 | 0.410 |
Why?
| | Reproducibility of Results | 10 | 2024 | 3416 | 0.410 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 89 | 0.400 |
Why?
| | Evoked Potentials, Visual | 1 | 2013 | 42 | 0.390 |
Why?
| | Gestational Age | 5 | 2023 | 989 | 0.380 |
Why?
| | Optic Atrophy, Hereditary, Leber | 2 | 2023 | 9 | 0.380 |
Why?
| | Adult | 34 | 2024 | 40872 | 0.380 |
Why?
| | Postoperative Period | 3 | 2026 | 351 | 0.380 |
Why?
| | Eye Infections, Bacterial | 5 | 1998 | 45 | 0.370 |
Why?
| | Telemedicine | 2 | 2020 | 966 | 0.370 |
Why?
| | Down Syndrome | 1 | 2019 | 525 | 0.360 |
Why?
| | Botulinum Toxins | 1 | 2013 | 48 | 0.360 |
Why?
| | Stress, Mechanical | 1 | 2014 | 494 | 0.360 |
Why?
| | Angiogenesis Inhibitors | 2 | 2010 | 239 | 0.350 |
Why?
| | Age Factors | 8 | 2021 | 3346 | 0.340 |
Why?
| | Chin | 2 | 2022 | 8 | 0.340 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2011 | 92 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 10 | 2019 | 3915 | 0.320 |
Why?
| | Cataract | 2 | 2023 | 238 | 0.320 |
Why?
| | Leukemic Infiltration | 2 | 2015 | 11 | 0.320 |
Why?
| | Candidemia | 2 | 2021 | 16 | 0.320 |
Why?
| | Optic Neuritis | 4 | 1999 | 44 | 0.310 |
Why?
| | Vestibular Nuclei | 1 | 2010 | 7 | 0.310 |
Why?
| | Oculomotor Nerve Diseases | 2 | 2021 | 14 | 0.310 |
Why?
| | Reoperation | 4 | 2020 | 637 | 0.310 |
Why?
| | Intraocular Pressure | 3 | 2021 | 330 | 0.300 |
Why?
| | Central Venous Pressure | 1 | 2009 | 17 | 0.300 |
Why?
| | Wet Macular Degeneration | 1 | 2010 | 58 | 0.300 |
Why?
| | Zellweger Syndrome | 1 | 2009 | 2 | 0.300 |
Why?
| | Jugular Veins | 1 | 2009 | 42 | 0.300 |
Why?
| | Vitamin A Deficiency | 1 | 2009 | 26 | 0.290 |
Why?
| | Recurrence | 4 | 2026 | 1139 | 0.290 |
Why?
| | Artifacts | 2 | 2021 | 143 | 0.290 |
Why?
| | Corneal Ulcer | 1 | 2009 | 20 | 0.290 |
Why?
| | Anterior Chamber | 2 | 2008 | 26 | 0.290 |
Why?
| | Infant, Premature | 2 | 2023 | 620 | 0.280 |
Why?
| | Observation | 3 | 2016 | 54 | 0.280 |
Why?
| | Incidence | 8 | 2021 | 2933 | 0.280 |
Why?
| | Accommodation, Ocular | 2 | 2020 | 15 | 0.280 |
Why?
| | Tennessee | 6 | 2008 | 57 | 0.280 |
Why?
| | Prospective Studies | 18 | 2024 | 8075 | 0.280 |
Why?
| | Phakic Intraocular Lenses | 1 | 2008 | 1 | 0.270 |
Why?
| | Postoperative Complications | 6 | 2010 | 2977 | 0.270 |
Why?
| | Optometry | 2 | 2006 | 9 | 0.270 |
Why?
| | Neural Pathways | 1 | 2010 | 317 | 0.270 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2008 | 56 | 0.270 |
Why?
| | Internationality | 1 | 2008 | 156 | 0.260 |
Why?
| | United States | 11 | 2026 | 16123 | 0.260 |
Why?
| | Cellulitis | 2 | 1998 | 54 | 0.260 |
Why?
| | Blindness, Cortical | 1 | 2007 | 6 | 0.260 |
Why?
| | Acrocephalosyndactylia | 1 | 2007 | 12 | 0.250 |
Why?
| | Tomography, Optical Coherence | 3 | 2021 | 270 | 0.250 |
Why?
| | Fovea Centralis | 4 | 2010 | 24 | 0.250 |
Why?
| | Pupil | 4 | 2000 | 22 | 0.240 |
Why?
| | Face | 1 | 2007 | 175 | 0.240 |
Why?
| | Antibodies, Monoclonal | 2 | 2010 | 1505 | 0.240 |
Why?
| | Oculomotor Nerve | 2 | 2021 | 9 | 0.230 |
Why?
| | Foundations | 1 | 2006 | 27 | 0.230 |
Why?
| | Eye Protective Devices | 2 | 2016 | 8 | 0.230 |
Why?
| | Diabetes Insipidus | 1 | 2005 | 6 | 0.230 |
Why?
| | Photorefractive Keratectomy | 1 | 2006 | 21 | 0.230 |
Why?
| | Septo-Optic Dysplasia | 1 | 2005 | 5 | 0.230 |
Why?
| | Visual Pathways | 3 | 2001 | 61 | 0.230 |
Why?
| | Opportunistic Infections | 1 | 2005 | 47 | 0.220 |
Why?
| | Middle Aged | 17 | 2024 | 36302 | 0.220 |
Why?
| | Vitreous Body | 5 | 2010 | 117 | 0.220 |
Why?
| | Marfan Syndrome | 1 | 2005 | 46 | 0.220 |
Why?
| | History, 21st Century | 1 | 2026 | 222 | 0.220 |
Why?
| | Reflex, Vestibulo-Ocular | 2 | 2001 | 31 | 0.210 |
Why?
| | Age Distribution | 4 | 2011 | 404 | 0.210 |
Why?
| | Practice Patterns, Physicians' | 2 | 2004 | 1372 | 0.210 |
Why?
| | Diagnosis, Differential | 7 | 2019 | 1512 | 0.210 |
Why?
| | History, 20th Century | 1 | 2026 | 328 | 0.210 |
Why?
| | Cornea | 1 | 2006 | 154 | 0.210 |
Why?
| | Canada | 1 | 2026 | 432 | 0.210 |
Why?
| | Brain Concussion | 2 | 2022 | 646 | 0.210 |
Why?
| | Exophthalmos | 1 | 2004 | 18 | 0.210 |
Why?
| | Muscles | 3 | 1991 | 330 | 0.200 |
Why?
| | Leukemia, Myeloid | 1 | 2004 | 48 | 0.200 |
Why?
| | Graves Ophthalmopathy | 1 | 2024 | 13 | 0.200 |
Why?
| | Aphakia, Postcataract | 1 | 2003 | 13 | 0.200 |
Why?
| | Medical Records | 2 | 2007 | 192 | 0.200 |
Why?
| | Contact Lenses | 1 | 2003 | 13 | 0.200 |
Why?
| | Nerve Fibers | 2 | 2021 | 105 | 0.200 |
Why?
| | Retinoscopy | 2 | 2016 | 3 | 0.200 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2023 | 75 | 0.200 |
Why?
| | Tonometry, Ocular | 2 | 2021 | 104 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 8 | 2014 | 2770 | 0.200 |
Why?
| | Xanthomatosis, Cerebrotendinous | 1 | 2023 | 5 | 0.200 |
Why?
| | Iris | 2 | 2005 | 23 | 0.200 |
Why?
| | Pseudotumor Cerebri | 2 | 2000 | 32 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2024 | 992 | 0.190 |
Why?
| | Birth Weight | 2 | 2023 | 517 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2013 | 1270 | 0.190 |
Why?
| | Hematoma, Subdural | 2 | 2000 | 20 | 0.190 |
Why?
| | Retinal Hemorrhage | 2 | 2000 | 21 | 0.190 |
Why?
| | Parvovirinae | 1 | 2022 | 5 | 0.190 |
Why?
| | Paralysis | 1 | 2023 | 69 | 0.190 |
Why?
| | Young Adult | 6 | 2023 | 14251 | 0.180 |
Why?
| | Aging | 3 | 2011 | 1973 | 0.180 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 235 | 0.180 |
Why?
| | Ophthalmologists | 1 | 2022 | 21 | 0.180 |
Why?
| | Eye Diseases, Hereditary | 1 | 2021 | 15 | 0.180 |
Why?
| | Receptors, Angiotensin | 1 | 2001 | 11 | 0.170 |
Why?
| | Physicians' Offices | 2 | 2016 | 18 | 0.170 |
Why?
| | Neonatal Screening | 1 | 2023 | 179 | 0.170 |
Why?
| | Vitrectomy | 3 | 2005 | 73 | 0.170 |
Why?
| | Pandemics | 2 | 2020 | 1711 | 0.170 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2001 | 56 | 0.170 |
Why?
| | Intubation | 2 | 2014 | 8 | 0.170 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2001 | 31 | 0.170 |
Why?
| | Dacryocystorhinostomy | 2 | 2014 | 13 | 0.170 |
Why?
| | Nasolacrimal Duct | 2 | 2014 | 12 | 0.170 |
Why?
| | Academies and Institutes | 1 | 2021 | 61 | 0.170 |
Why?
| | Daucus carota | 1 | 2000 | 2 | 0.170 |
Why?
| | Aphakia | 1 | 2000 | 2 | 0.170 |
Why?
| | Pilot Projects | 5 | 2021 | 1897 | 0.160 |
Why?
| | Retinal Ganglion Cells | 1 | 2021 | 121 | 0.160 |
Why?
| | Sports Medicine | 1 | 2022 | 119 | 0.160 |
Why?
| | Time Factors | 4 | 2026 | 7133 | 0.160 |
Why?
| | Masks | 1 | 2021 | 70 | 0.160 |
Why?
| | Battered Child Syndrome | 1 | 2000 | 7 | 0.160 |
Why?
| | United Arab Emirates | 1 | 2020 | 6 | 0.160 |
Why?
| | Videoconferencing | 1 | 2020 | 65 | 0.150 |
Why?
| | Subarachnoid Hemorrhage, Traumatic | 1 | 1999 | 5 | 0.150 |
Why?
| | Low Tension Glaucoma | 1 | 2019 | 1 | 0.150 |
Why?
| | Horner Syndrome | 2 | 1996 | 7 | 0.150 |
Why?
| | Leukomalacia, Periventricular | 1 | 2019 | 9 | 0.150 |
Why?
| | Vision, Ocular | 1 | 2000 | 47 | 0.150 |
Why?
| | Sex Distribution | 2 | 2011 | 388 | 0.150 |
Why?
| | Sports | 1 | 2022 | 212 | 0.150 |
Why?
| | Planning Techniques | 1 | 2019 | 15 | 0.150 |
Why?
| | Glaucoma, Open-Angle | 1 | 2021 | 104 | 0.150 |
Why?
| | Bacteremia | 2 | 2019 | 222 | 0.150 |
Why?
| | Physical Examination | 2 | 2019 | 244 | 0.150 |
Why?
| | Syndrome | 1 | 2020 | 381 | 0.150 |
Why?
| | Temporal Lobe | 1 | 1999 | 107 | 0.140 |
Why?
| | Electroretinography | 1 | 1998 | 51 | 0.140 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 1998 | 17 | 0.140 |
Why?
| | Eye Infections, Viral | 1 | 1998 | 12 | 0.140 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 1998 | 20 | 0.140 |
Why?
| | Polymorphism, Genetic | 1 | 2001 | 615 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 251 | 0.140 |
Why?
| | Costs and Cost Analysis | 1 | 2019 | 221 | 0.140 |
Why?
| | Eyelid Diseases | 1 | 1998 | 26 | 0.140 |
Why?
| | Orbital Diseases | 1 | 1998 | 37 | 0.140 |
Why?
| | Haemophilus Infections | 1 | 1998 | 46 | 0.140 |
Why?
| | Pupil Disorders | 1 | 1997 | 7 | 0.130 |
Why?
| | Aged | 8 | 2024 | 26215 | 0.130 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 393 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1988 | 65 | 0.130 |
Why?
| | Motion Perception | 1 | 1998 | 20 | 0.130 |
Why?
| | Intracranial Hypertension | 1 | 1998 | 42 | 0.130 |
Why?
| | Fatal Outcome | 2 | 2015 | 305 | 0.130 |
Why?
| | Retinal Diseases | 1 | 1998 | 101 | 0.130 |
Why?
| | Craniocerebral Trauma | 1 | 1999 | 179 | 0.130 |
Why?
| | Hydrocephalus | 2 | 2010 | 111 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2010 | 552 | 0.130 |
Why?
| | Spleen | 1 | 2019 | 508 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1812 | 0.130 |
Why?
| | p-Hydroxyamphetamine | 1 | 1996 | 1 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 971 | 0.130 |
Why?
| | Synapses | 3 | 1991 | 439 | 0.130 |
Why?
| | Conjunctivitis, Viral | 1 | 1996 | 3 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2018 | 150 | 0.120 |
Why?
| | Quality of Life | 5 | 2022 | 3210 | 0.120 |
Why?
| | Conjunctivitis, Bacterial | 1 | 1996 | 12 | 0.120 |
Why?
| | Keratitis | 1 | 1996 | 20 | 0.120 |
Why?
| | Sarcopenia | 1 | 2018 | 91 | 0.120 |
Why?
| | Volunteers | 2 | 2010 | 39 | 0.120 |
Why?
| | Wounds, Nonpenetrating | 1 | 1999 | 321 | 0.120 |
Why?
| | Eye Foreign Bodies | 2 | 1994 | 23 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2019 | 2933 | 0.120 |
Why?
| | Sensory Thresholds | 4 | 1999 | 31 | 0.120 |
Why?
| | Retinal Detachment | 2 | 1997 | 73 | 0.120 |
Why?
| | Proteomics | 1 | 2023 | 1188 | 0.120 |
Why?
| | Piperazines | 1 | 1998 | 375 | 0.120 |
Why?
| | Respiration, Artificial | 1 | 2021 | 714 | 0.110 |
Why?
| | Prosthesis Implantation | 1 | 1997 | 156 | 0.110 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1062 | 0.110 |
Why?
| | Biopsy, Needle | 2 | 2011 | 185 | 0.110 |
Why?
| | Vitamin A | 2 | 2009 | 62 | 0.110 |
Why?
| | Prognosis | 4 | 2015 | 4329 | 0.110 |
Why?
| | Myelinolysis, Central Pontine | 1 | 1995 | 3 | 0.110 |
Why?
| | Athletic Injuries | 1 | 2022 | 573 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8346 | 0.110 |
Why?
| | Functional Laterality | 2 | 2011 | 240 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 1998 | 821 | 0.110 |
Why?
| | Weight Loss | 1 | 2000 | 859 | 0.110 |
Why?
| | Parents | 1 | 2003 | 1407 | 0.110 |
Why?
| | Orthoptics | 1 | 2014 | 2 | 0.110 |
Why?
| | Epilepsy | 1 | 1999 | 390 | 0.110 |
Why?
| | Anti-Bacterial Agents | 2 | 1996 | 1925 | 0.100 |
Why?
| | Antifungal Agents | 2 | 2011 | 152 | 0.100 |
Why?
| | Retinal Neovascularization | 1 | 1994 | 29 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2014 | 71 | 0.100 |
Why?
| | Cephalosporins | 1 | 1994 | 45 | 0.100 |
Why?
| | Developmental Disabilities | 1 | 2016 | 281 | 0.100 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 61 | 0.100 |
Why?
| | Cryotherapy | 1 | 2013 | 21 | 0.100 |
Why?
| | Anti-Dyskinesia Agents | 1 | 2013 | 8 | 0.100 |
Why?
| | Vancomycin | 1 | 1994 | 95 | 0.100 |
Why?
| | Facial Paralysis | 1 | 1993 | 23 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1993 | 59 | 0.090 |
Why?
| | Algorithms | 1 | 2001 | 1850 | 0.090 |
Why?
| | Interferon-alpha | 1 | 1994 | 193 | 0.090 |
Why?
| | Bevacizumab | 2 | 2010 | 168 | 0.090 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1993 | 80 | 0.090 |
Why?
| | Acute Disease | 4 | 2004 | 1036 | 0.090 |
Why?
| | Conjunctival Diseases | 1 | 1992 | 23 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 1993 | 120 | 0.090 |
Why?
| | Hyperthermia, Induced | 1 | 2013 | 120 | 0.090 |
Why?
| | Brain Ischemia | 1 | 1996 | 359 | 0.090 |
Why?
| | Injections, Intramuscular | 1 | 2013 | 146 | 0.090 |
Why?
| | Dependovirus | 2 | 2023 | 78 | 0.090 |
Why?
| | Silicone Oils | 1 | 1992 | 37 | 0.090 |
Why?
| | Brain | 2 | 2001 | 2969 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2015 | 532 | 0.090 |
Why?
| | Macular Degeneration | 1 | 1994 | 191 | 0.090 |
Why?
| | Recovery of Function | 2 | 2010 | 716 | 0.080 |
Why?
| | Sarcoidosis | 1 | 1993 | 163 | 0.080 |
Why?
| | Ranibizumab | 1 | 2010 | 21 | 0.080 |
Why?
| | Genetic Therapy | 2 | 2023 | 316 | 0.080 |
Why?
| | Administration, Oral | 2 | 2009 | 867 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 26 | 0.080 |
Why?
| | Los Angeles | 1 | 2010 | 73 | 0.080 |
Why?
| | Remission, Spontaneous | 1 | 2010 | 39 | 0.080 |
Why?
| | Patient Care Management | 1 | 2010 | 56 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 74 | 0.080 |
Why?
| | Orbit | 1 | 2010 | 66 | 0.080 |
Why?
| | Saccule and Utricle | 1 | 2010 | 13 | 0.080 |
Why?
| | Torsion Abnormality | 1 | 2010 | 20 | 0.080 |
Why?
| | Disease Progression | 3 | 2010 | 2865 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 112 | 0.080 |
Why?
| | Injections | 1 | 2010 | 199 | 0.080 |
Why?
| | Semicircular Canals | 1 | 2010 | 37 | 0.080 |
Why?
| | Seizures | 2 | 2007 | 485 | 0.080 |
Why?
| | Formamides | 1 | 1989 | 8 | 0.070 |
Why?
| | User-Computer Interface | 1 | 2010 | 165 | 0.070 |
Why?
| | Hospitals, Veterans | 1 | 2010 | 258 | 0.070 |
Why?
| | Research Design | 2 | 2018 | 1139 | 0.070 |
Why?
| | Infratentorial Neoplasms | 1 | 2010 | 71 | 0.070 |
Why?
| | Candida | 2 | 2019 | 46 | 0.070 |
Why?
| | Electrophysiology | 1 | 1989 | 218 | 0.070 |
Why?
| | Reflex, Pupillary | 2 | 1999 | 6 | 0.070 |
Why?
| | Hong Kong | 1 | 2008 | 7 | 0.070 |
Why?
| | Ultrasonography | 2 | 2010 | 788 | 0.070 |
Why?
| | Intermediate Filament Proteins | 1 | 1988 | 57 | 0.070 |
Why?
| | Mutation, Missense | 1 | 2010 | 335 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2009 | 145 | 0.070 |
Why?
| | Observer Variation | 1 | 2009 | 357 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 177 | 0.070 |
Why?
| | Spinal Dysraphism | 1 | 2010 | 110 | 0.070 |
Why?
| | Brazil | 1 | 2008 | 179 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 184 | 0.070 |
Why?
| | Hypoxia, Brain | 1 | 2007 | 9 | 0.060 |
Why?
| | Preoperative Care | 1 | 2010 | 380 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1751 | 0.060 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2007 | 16 | 0.060 |
Why?
| | Eye Injuries | 2 | 2000 | 53 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2383 | 0.060 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 43 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 653 | 0.060 |
Why?
| | Muscle Contraction | 1 | 1989 | 429 | 0.060 |
Why?
| | International Agencies | 1 | 2006 | 30 | 0.060 |
Why?
| | Treatment Failure | 1 | 2007 | 360 | 0.060 |
Why?
| | Jaundice, Neonatal | 1 | 2005 | 8 | 0.060 |
Why?
| | Lasers, Excimer | 1 | 2006 | 30 | 0.060 |
Why?
| | Alaska | 1 | 2006 | 77 | 0.060 |
Why?
| | Hypopituitarism | 1 | 2005 | 16 | 0.060 |
Why?
| | Eye Injuries, Penetrating | 1 | 2005 | 19 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2010 | 2064 | 0.060 |
Why?
| | Rats, Inbred F344 | 3 | 1991 | 268 | 0.050 |
Why?
| | Central Nervous System | 1 | 2007 | 282 | 0.050 |
Why?
| | Reference Values | 3 | 2007 | 798 | 0.050 |
Why?
| | Legislation, Medical | 1 | 2004 | 11 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2010 | 599 | 0.050 |
Why?
| | Urinary Tract Infections | 1 | 2007 | 210 | 0.050 |
Why?
| | Voluntary Health Agencies | 1 | 2004 | 6 | 0.050 |
Why?
| | Treatment Refusal | 1 | 2005 | 99 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2004 | 80 | 0.050 |
Why?
| | Blood Glucose | 2 | 2008 | 2344 | 0.050 |
Why?
| | Cholestanol | 1 | 2023 | 4 | 0.050 |
Why?
| | NADH Dehydrogenase | 1 | 2023 | 20 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2024 | 116 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 3195 | 0.050 |
Why?
| | Random Allocation | 1 | 2003 | 365 | 0.050 |
Why?
| | Premature Birth | 1 | 2007 | 390 | 0.050 |
Why?
| | Kidney | 1 | 2010 | 1496 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2005 | 610 | 0.050 |
Why?
| | Scotoma | 2 | 1999 | 6 | 0.050 |
Why?
| | Animals | 6 | 2014 | 38097 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2967 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2007 | 587 | 0.050 |
Why?
| | Blindness | 1 | 2002 | 51 | 0.050 |
Why?
| | Saccades | 1 | 2022 | 46 | 0.040 |
Why?
| | Bile Acids and Salts | 1 | 2023 | 163 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2219 | 0.040 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2001 | 8 | 0.040 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2001 | 25 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 211 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 588 | 0.040 |
Why?
| | Inflammation | 2 | 2023 | 2883 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2022 | 335 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2005 | 480 | 0.040 |
Why?
| | Rats | 4 | 1991 | 5585 | 0.040 |
Why?
| | Vitreous Hemorrhage | 1 | 2000 | 10 | 0.040 |
Why?
| | Geniculate Bodies | 1 | 2019 | 22 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2001 | 368 | 0.040 |
Why?
| | Microbiological Techniques | 3 | 1995 | 30 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2000 | 82 | 0.040 |
Why?
| | Bacteria | 3 | 1995 | 766 | 0.040 |
Why?
| | Siblings | 1 | 2020 | 196 | 0.040 |
Why?
| | Muscle Development | 2 | 1991 | 112 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2007 | 365 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2001 | 5922 | 0.040 |
Why?
| | Automation | 1 | 1999 | 104 | 0.040 |
Why?
| | Visual Cortex | 1 | 2019 | 84 | 0.040 |
Why?
| | Blood Sedimentation | 1 | 1998 | 37 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1998 | 29 | 0.040 |
Why?
| | Optic Nerve | 1 | 1998 | 67 | 0.030 |
Why?
| | Streptococcus | 1 | 1998 | 29 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 461 | 0.030 |
Why?
| | Sildenafil Citrate | 1 | 1998 | 60 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2020 | 182 | 0.030 |
Why?
| | Streptococcal Infections | 2 | 1998 | 171 | 0.030 |
Why?
| | Haemophilus influenzae | 1 | 1998 | 68 | 0.030 |
Why?
| | Probability | 1 | 1999 | 308 | 0.030 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 1998 | 25 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2007 | 1331 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.030 |
Why?
| | Sulfones | 1 | 1998 | 127 | 0.030 |
Why?
| | Postoperative Care | 1 | 2019 | 286 | 0.030 |
Why?
| | Purines | 1 | 1998 | 187 | 0.030 |
Why?
| | Animals, Newborn | 2 | 1991 | 896 | 0.030 |
Why?
| | HIV | 1 | 1998 | 251 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2000 | 1330 | 0.030 |
Why?
| | Molluscum Contagiosum | 1 | 1996 | 4 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 61 | 0.030 |
Why?
| | Trachoma | 1 | 1996 | 2 | 0.030 |
Why?
| | Corneal Diseases | 1 | 1997 | 46 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1997 | 264 | 0.030 |
Why?
| | Viral Load | 1 | 1998 | 526 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 224 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1996 | 47 | 0.030 |
Why?
| | Neutropenia | 1 | 1997 | 154 | 0.030 |
Why?
| | Brain Edema | 1 | 1996 | 62 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.030 |
Why?
| | Electroencephalography | 1 | 1999 | 563 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 553 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 835 | 0.030 |
Why?
| | Carotid Artery, Internal | 1 | 1995 | 45 | 0.030 |
Why?
| | Carotid Artery Diseases | 1 | 1995 | 70 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2000 | 489 | 0.030 |
Why?
| | Brain Injuries | 1 | 2000 | 507 | 0.030 |
Why?
| | Equipment Contamination | 1 | 1995 | 67 | 0.030 |
Why?
| | Fractures, Bone | 1 | 2000 | 428 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1300 | 0.030 |
Why?
| | Fundus Oculi | 1 | 1994 | 89 | 0.030 |
Why?
| | Child Abuse | 1 | 2020 | 553 | 0.030 |
Why?
| | Ceftazidime | 1 | 1994 | 7 | 0.030 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2014 | 11 | 0.030 |
Why?
| | Anesthesia, Local | 1 | 2014 | 26 | 0.030 |
Why?
| | Aminoglycosides | 1 | 1994 | 30 | 0.030 |
Why?
| | Corneal Injuries | 1 | 1994 | 42 | 0.020 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2014 | 79 | 0.020 |
Why?
| | Karyotyping | 1 | 1993 | 106 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6085 | 0.020 |
Why?
| | Emulsions | 1 | 1992 | 59 | 0.020 |
Why?
| | Foreign-Body Reaction | 1 | 1992 | 34 | 0.020 |
Why?
| | Prednisone | 1 | 1993 | 226 | 0.020 |
Why?
| | Eye Enucleation | 1 | 2011 | 15 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1993 | 507 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 4090 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3634 | 0.020 |
Why?
| | Primary Health Care | 1 | 2022 | 1737 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1791 | 0.020 |
Why?
| | Muscle Denervation | 1 | 1991 | 8 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3170 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1368 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2010 | 51 | 0.020 |
Why?
| | Injections, Intraocular | 1 | 2010 | 14 | 0.020 |
Why?
| | Tubocurarine | 1 | 1989 | 6 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 413 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 410 | 0.020 |
Why?
| | Exons | 1 | 2010 | 364 | 0.020 |
Why?
| | Fixatives | 1 | 1988 | 13 | 0.020 |
Why?
| | RNA Splicing | 1 | 2010 | 284 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 312 | 0.020 |
Why?
| | Ganglia, Spinal | 1 | 1988 | 88 | 0.020 |
Why?
| | Neurofilament Proteins | 1 | 1988 | 79 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4302 | 0.020 |
Why?
| | Selection Bias | 1 | 2007 | 38 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1988 | 365 | 0.020 |
Why?
| | Reflex | 1 | 1987 | 70 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1723 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 430 | 0.020 |
Why?
| | Hindlimb | 1 | 1987 | 132 | 0.020 |
Why?
| | Obesity | 1 | 2000 | 3118 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4116 | 0.020 |
Why?
| | Axons | 1 | 1988 | 204 | 0.020 |
Why?
| | Lung Diseases | 1 | 1993 | 782 | 0.020 |
Why?
| | Body Weight | 1 | 1991 | 972 | 0.020 |
Why?
| | Phosphoproteins | 1 | 1988 | 337 | 0.010 |
Why?
| | Motor Neurons | 1 | 1988 | 236 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2883 | 0.010 |
Why?
| | Spinal Cord | 1 | 1988 | 382 | 0.010 |
Why?
| | Action Potentials | 1 | 1989 | 502 | 0.010 |
Why?
| | Internet | 1 | 2010 | 693 | 0.010 |
Why?
| | Korea | 1 | 2005 | 18 | 0.010 |
Why?
| | Electromyography | 1 | 1987 | 419 | 0.010 |
Why?
| | Odds Ratio | 1 | 2007 | 1083 | 0.010 |
Why?
| | Video Games | 1 | 2005 | 30 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 782 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2006 | 268 | 0.010 |
Why?
| | Sympathectomy, Chemical | 1 | 2004 | 5 | 0.010 |
Why?
| | Reading | 1 | 2005 | 135 | 0.010 |
Why?
| | Patient Selection | 1 | 2007 | 739 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2006 | 644 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 3752 | 0.010 |
Why?
| | Neurologic Examination | 1 | 2000 | 132 | 0.010 |
Why?
| | Cerebrospinal Fluid Pressure | 1 | 1999 | 5 | 0.010 |
Why?
| | Spinal Puncture | 1 | 1999 | 18 | 0.010 |
Why?
| | Acetazolamide | 1 | 1999 | 26 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1999 | 44 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1999 | 65 | 0.010 |
Why?
| | Reaction Time | 1 | 1999 | 434 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 6032 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1999 | 1043 | 0.010 |
Why?
| | Facial Pain | 1 | 1995 | 12 | 0.010 |
Why?
| | Isotonic Solutions | 1 | 1995 | 42 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 164 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 2094 | 0.010 |
Why?
| | Magnetic Resonance Angiography | 1 | 1995 | 251 | 0.010 |
Why?
| | Radiography | 1 | 1995 | 853 | 0.010 |
Why?
|
|
Donahue's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|